Inclusion Criteria:  Participated in Study mRNA-3927-P101. Completed the EOT Visit in Study mRNA-3927-P101 within 10 days of first dose of mRNA-3927 in current study.  Exclusion Criteria:  Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator. Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study. History of liver and/or kidney transplant.